Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302.

Can Urol Assoc J 2019 Jun;13(6):192-200

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Introduction: Radiographic imaging is used to monitor disease progression for men with metastatic castrate-resistant prostate cancer (mCRPC). The optimal frequency of imaging, a costly and limited resource, is not known. Our objective was to identify predictors of radiographic progression to inform the frequency of imaging for men with mCRPC.

Methods: We accessed data for men with chemotherapy-naive mCRPC in the abiraterone acetate plus prednisone (AA-P) group of a randomized trial (COU-AA-302) (n=546). We used Cox proportional hazards modelling to identify predictors of time to progression. We divided patients into groups based on the most important predictors and estimated the probability of radiographic progression-free survival (RPFS) at six and 12 months.

Results: Baseline disease and change in prostate-specific antigen (PSA) at eight weeks were the strongest determinants of RPFS. The probability of RPFS for men with bone-only disease and a ≥50% fall in PSA was 93% (95% confidence interval [CI] 87-96) at six months and 80% (95% CI 72-86) at 12 months. In contrast, the probability of RPFS for men with bone and soft tissue metastasis and <50% fall in PSA was 55% (95% CI 41-67) at six months and 34% (95% CI 22-47) at 12 months. These findings should be externally validated.

Conclusions: Patients with chemotherapy-naive mCRPC treated with first-line AA-P can be divided into groups with significantly different risks of radiographic progression based on a few clinically available variables, suggesting that imaging schedules could be individualized.

Download full-text PDF

Source
https://cuaj.ca/index.php/journal/article/view/5586
Publisher Site
http://dx.doi.org/10.5489/cuaj.5586DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570594PMC
June 2019
38 Reads

Publication Analysis

Top Keywords

prostate cancer
8
cancer mcrpc
8
radiographic progression
8
identify predictors
8
rpfs men
8
castrate-resistant prostate
8
metastatic castrate-resistant
8
probability rpfs
8
frequency imaging
8
men
5
n=546 cox
4
trial cou-aa-302
4
cou-aa-302 n=546
4
confidence interval
4
interval [ci]
4
95% confidence
4
modelling identify
4
predictors time
4
hazards modelling
4
randomized trial
4

Similar Publications